Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
Dateline City:
KENILWORTH, N.J. & HOUSTON
KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
DNAtrix today announced they have entered into an oncology clinical
study collaboration to evaluate the efficacy and safety of DNX-2401,
DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA®
(pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered
study of patients with recurrent glioblastoma, the most aggressive form
of brain cancer for which there is no cure.
Language:
English
Contact:
MerckMedia Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325Investor Relations:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orDNAtrixInvestor/Media Relations:Imran Alibhai, Ph.D.ialibhai@dnatrix.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Drugs & Pharmacology | Immunotherapy | Merck | Neurology | Study